ADC Therapeutics SA Market Cap ($143.73 Million)
Market Cap & Net Worth: ADC Therapeutics SA (ADCT)
ADC Therapeutics SA market cap. ADC Therapeutics SA (NYSE:ADCT) has a market capitalization of $143.73 Million ($143.73 Million) as of November 1, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #17623 globally and #4181 in its home market, demonstrating a -4.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADC Therapeutics SA's stock price $1.53 by its total outstanding shares 127191158 (127.19 Million). Also see ADC Therapeutics SA cash flow conversion for how efficiently the company converts equity into cash flow.
ADC Therapeutics SA Market Cap History (2020–2026)
ADC Therapeutics SA market cap history from 2020 to 2026. Data shows change from $4.07 Billion to $194.60 Million (-36.79% CAGR). Check ADCT stock price and chart for real-time trading data and today's change.
ADC Therapeutics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADC Therapeutics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ADCT shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.52x
ADC Therapeutics SA's market cap is 5.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.57 Billion | $33.92 Million | -$230.03 Million | 75.75x | N/A |
| 2022 | $488.41 Million | $209.91 Million | -$157.13 Million | 2.33x | N/A |
| 2023 | $211.14 Million | $69.56 Million | -$240.05 Million | 3.04x | N/A |
| 2024 | $253.11 Million | $70.84 Million | -$157.85 Million | 3.57x | N/A |
| 2025 | $448.98 Million | $81.36 Million | -$142.62 Million | 5.52x | N/A |
Competitor Companies of ADCT by Market Capitalization
Companies near ADC Therapeutics SA in the global market cap rankings as of November 1, 2026. Also see ADCT total assets for a full breakdown of the balance sheet.
Key companies related to ADC Therapeutics SA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of ADC Therapeutics SA (2020–2026)
Market capitalization of ADC Therapeutics SA from 2020 to today. Between 2020 and today, ADC Therapeutics SA's market cap moved from $4.07 Billion to $ 194.60 Million, with a yearly change of -36.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $194.60 Million | -56.66% |
| 2025 | $448.98 Million | +77.39% |
| 2024 | $253.11 Million | +19.88% |
| 2023 | $211.14 Million | -56.77% |
| 2022 | $488.41 Million | -80.99% |
| 2021 | $2.57 Billion | -36.89% |
| 2020 | $4.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of ADC Therapeutics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $143.73 Million USD |
| MoneyControl | $143.73 Million USD |
| MarketWatch | $143.73 Million USD |
| marketcap.company | $143.73 Million USD |
| Reuters | $143.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more